Company intelligence / Profile preview

Holistic Frequency Therapeutics

Lexington, Massachusetts, United States

Ownership: Private
Employees: ~55
Development stage: Other

Overview

Frequency Therapeutics developed small-molecule therapies to activate progenitor cells for tissue regeneration, with its lead candidate FX‑322 showing some early promise in sensorineural hearing loss but ultimately failing to meet endpoints in Phase 2b. The company discontinued all hearing loss programs and pivoted to preclinical work on remyelination in multiple sclerosis before being acquired by Korro Bio. As of November 2023, the company no longer exists independently and its pipeline has been absorbed or discontinued post-merger.

Therapeutic areas: Neurology
Modalities: Small moleculeNanoparticle
Industry: Biotech

Partnerships

Hearing Life

Beyond the preview

Go deeper on Holistic Frequency Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Holistic Frequency Therapeutics.

Explore the full profile